Login

Forgot your password?
New User?
Remember me
banner banner

You are here:Home » Molecular Biology » MB-Peptides » AMP Activated Protein Kinase beta1,2, Human (AMPK- b1,2) Control Peptide

AMP Activated Protein Kinase beta1,2, Human (AMPK- b1,2) Control Peptide

Pricing

  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.

Specifications

A 15-aa peptide sequence mapping near the C-terminus of human AMPK-b1/2 (1).
Catalog #A1475-03G
In cells, excess of metabolic fuel is converted into fatty acids in cytosol and oxidized later in mitochondria to generate ATP and acetyl-CoA. In fatty acid synthesis, catalytic formation of malonyl-CoA (precursor for long-chain fatty acyl-CoA, LCFA-CoA) from acetyl-CoA by Acetyl-CoA carboxylase (ACC-1) is the rate limiting step. The translocation of LCFA-CoA from cytosol to mitochondria, catalyzed by two carnitine palmitoyl transferases (CPT-1 & CPT-2) and regulated by ACC-2, is the rate limiting step of mitochondrial fatty acid ?-oxidation. Activities of ACC-1, ACC-2 and other key proteins of carbohydrate and fat metabolism are regulated by their phosphorylation by 5'-AMP-activated protein kinase (AMPK). AMPK switches-off biosynthetic processes when ATP levels are depleted and AMP rises in response to fuel deficiency and treatments like heat shock, ischaemia and exercise. A defect in AMPK switch leads to insulin resistance, dyslipidemia, ketosis resistance and other metabolic derangements in Type 2 diabetes. AMPK also regulates cholesterol biosynthesis via phosphorylation and inactivation of hormone-sensitive lipase and hydroxymethylglutaryl-CoA resuctase. It also appears to act as a metabolic stress-sensing protein kinase switching off biosynthetic pathway when ATP levels are depleted and when 5-AMP rises in response to fuel limitation and or hypoxia.
AMPK is a heterotrimer of a catalytic subunit a (~63kD), and two non-catalytic regulatory subunits, b (~40kD) and g (~38kD). These subunits exist in multiple isoforms (a1, a2, b1, b2, g1 and g2). Coexpression of all three subunit is required for kinase activity. AMPK-beta acts as a scaffold vial which trimeric complex of AMPK assembles, with the a-subunit binding to its KIS domain and the g-subunit binding to its KIS domain and the g-subunit binding to its ACS domain. AMPK-beta 1 (mouse/rat/human 270-aa, ~38kD, chromosome 12q24.1) and AMPK Beta-2 (mouse/rat, 271-aa, human 270-aa, ~34kD) share ~70% identity. Both isoform contribute equally to the AMPK activity. AMPK-b1 is highly expressed in liver and brain and low levels in kidney and skeletal muscle. AMPK-b2 is most abundant in skeletal muscle with low levels in kidney, liver, and lung.
SourceHuman synthetic peptide
PurityHighly purified
ConcentrationAs reported
FormSupplied as a liquid in PBS, pH 7.2
Specificity100% conserved in human, mouse and rat AMPK-b1 and AMPK-b2, 93% conserved in drosophila proteins and 100% conserved in C. elegans F55F3.1.p protein (269-aa), Y47D3A.15.p protein (274-aa). Anti-AMPKB11 recognize both b1 and b2 isoform of AMPK. No significant sequence homology seen with AMPK-a or g-isoforms
Important NoteThis product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.


External Links